Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114452 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction
A Phase 1 study of Myocardial Infarction, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 15
- Study locations
NCT00114452: Completed Phase 1 study of Myocardial Infarction, sponsored by Mesoblast.
NCT00114452 is a Phase 1 study of Myocardial Infarction that has completed, run by Mesoblast. The registered enrollment target is 60 participants, below the 4,681-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (99% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00114452, a Phase 1 study of Myocardial Infarction, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of the study is to determine whether adult stem cells \[Provacel™(PUMP1)\] are safe and possibly effective in the treatment of acute myocardial infarction (heart attack).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Provacel
Study Locations (15)
Maryland
- Johns Hopkins University - Baltimore
- Washington Adventist - Takoma Park
New York
- Columbia Presbyterian Hospital - New York
- University of Rochester - Strong Memorial - Rochester
Texas
- Austin Heart Institute - Austin
- Texas Medical School - Houston
Arizona
- Arizona Heart Institute - Phoenix
California
- University of California - San Diego; Thornton - San Diego
District of Columbia
- Washington Hospital Center - Washington D.C.
Illinois
- Rush University Medical Center - Chicago
Indiana
- The Care Group - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-03-22 |
| Est. Completion | 2008-04-24 |
| Phase | Phase 1 |
What the finished NCT00114452 record still lists
NCT00114452 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 4,681-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00114452 lists 15 locations in 12 states (Maryland, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT00114452 about?
NCT00114452 is a clinical study titled "Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction". The purpose of the study is to determine whether adult stem cells \[Provacel™(PUMP1)\] are safe and possibly effective in the treatment of acute myocardial infarction (heart attack).
What is the current status of trial NCT00114452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2005-03-22. Estimated completion is 2008-04-24.
What conditions does trial NCT00114452 study?
This clinical trial studies the following conditions: Myocardial Infarction.
What interventions are being tested in trial NCT00114452?
The interventions under investigation include: Placebo (BIOLOGICAL), Provacel (BIOLOGICAL).
Who is sponsoring clinical trial NCT00114452?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00114452 being conducted?
This trial has 15 study locations across Arizona, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00114452's enrollment target sits among peer trials
60 56th of 64 higher than 9 of 64 other Myocardial Infarction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuroinflammation After Myocardial Infarction - Imaging Substudy
ACTIVE NOT RECRUITING · Phase 1
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
Women's Heart Attack Research Program: Stress Ancillary Study
RECRUITING · NA
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Heart Attack Research Program: Platelet Sub-Study (HARP)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI